UNSPSC 51434926: Deserpidine/methyclothiazide

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class CV400. This VA Drug Class (CV400) classifies this compound as belonging to the group ANTIHYPERTENSIVE COMBINATIONS.

UNSPSC 51434926 Deserpidine/methyclothiazide is a Commodity code that captures a narrow pharmaceutical product line, though recent state and local solicitations tagged with this code actually reflect broader emergency medical and pharmacy benefit procurements. State and local governments do solicit this specific combination antihypertensive agent, but the recent opportunities signal wider demand for emergency medications, generic pharmaceuticals, and direct-to-manufacturer prescription fulfillment arrangements. Issuing bodies include municipal fire and rescue services (Tampa Fire Rescue), state health and human services agencies (Texas HHS Commission), and multistate cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance). The code shows activity across municipal departments and state health agencies seeking to stock controlled formularies and manage pharmacy supply chains through wholesaler networks and direct manufacturer relationships.

Recent solicitations span Florida, Texas, and Minnesota with interstate scope through cooperative purchasing. The City of Tampa Purchasing Department issued IFB 26P00188 in April 2026 for Advanced Life Support Medications—including labetalol, epinephrine, adenosine, and diltiazem—with a response deadline of April 8, 2026 and an estimated contract value of $40,000, incorporating a 5 percent small local business enterprise bid discount. The Minnesota Department of Administration's Office of State Procurement issued RFP S1070000015802 through MMCAP in January 2026 for generic multi-source pharmaceuticals and OTC products distributed across participating state and local facilities in Minnesota and Oregon, with proposals due March 26, 2026 and an effective award date of July 1, 2026. The Texas Health and Human Services Commission issued RFI HHS0017013 in April 2026 to gather vendor capabilities on direct-to-manufacturer prescription programs, signaling exploration of new supply-chain models for pharmacy benefit management. The code shows episodic but recurring activity among municipal emergency services and state procurement alliances managing medication formularies.